CNS & Neurological Disorders - Drug Targets
Title:Meet the Editorial Board Member
Volume: 21 Issue: 8
Author(s): Claire F. Evans
Affiliation:
Export Options
About this article
Cite this article as:
Evans F. Claire, Meet the Editorial Board Member, CNS & Neurological Disorders - Drug Targets 2022; 21 (8) . https://dx.doi.org/10.2174/187152732108220420090401
DOI https://dx.doi.org/10.2174/187152732108220420090401 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Latest Advancements on Serotonin and Dopamine Transporters in Lymphocytes
Mini-Reviews in Medicinal Chemistry Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Strategies to Create a Regenerating Environment for the Injured Spinal Cord
Current Pharmaceutical Design Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?
Current Pharmaceutical Design A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Therapeutic Targeting of Chemokines and Chemokine Receptors in Multiple Sclerosis: Opportunities and Challenges
CNS & Neurological Disorders - Drug Targets Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Cytochrome P450 in Neurological Disease
Current Drug Metabolism Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Current Medicinal Chemistry Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Ex Vivo Gene Therapy and Vision
Current Gene Therapy Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Current Diabetes Reviews Involvement of Cytosolic Phospholipase A2, Calcium Independent Phospholipase A2 and Plasmalogen Selective Phospholipase A2 in Neurodegenerative and Neuropsychiatric Conditions
Current Medicinal Chemistry The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Involvement of the Blood-Brain Barrier in Metabolic Regulation
CNS & Neurological Disorders - Drug Targets Transient Focal Lesions in the Splenium of the Corpus Callosum with Restricted Diffusion: An Enigma
Current Medical Imaging A Systematic Review of the Potential Herbal Sources of Future Drugs Effective in Oxidant-Related Diseases
Inflammation & Allergy - Drug Targets (Discontinued)